<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043519</url>
  </required_header>
  <id_info>
    <org_study_id>S2021485</org_study_id>
    <nct_id>NCT05043519</nct_id>
  </id_info>
  <brief_title>Phase I/II Clinical Trial of NP41 for Cranial Nerve Fluorescence Imaging</brief_title>
  <official_title>Phase I/II Clinical Trial of NP41 Molecular Targeted Fluorescence Imaging for Cranial Nerve Visualization During Neurosurgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preclinical evidence has shown that NP41 is a novel nerve-binding peptide with safe&#xD;
      pharmacokinetics. Fluorescently labeled NP41 is effective for the intraoperative&#xD;
      visualization of cranial nerves during neurosurgery. This Phase I/II clinical trial is aimed&#xD;
      to investigate the safety and validity of FAM-NP41 for the fluorescence imaging of cranial&#xD;
      nerves. In the Phase I trial, biological safety and adverse events will be evaluated, and&#xD;
      pharmacokinetic parameters will be measured. In the Phase II trial, the sensitivity and&#xD;
      specificity of FAM-NP41 for the fluorescence imaging of cranial nerves will be investigated,&#xD;
      and the signal-to-background ratio will be calculated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>0~24 hours after the drug administration</time_frame>
    <description>Half-life for distribution, half-life for elimination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatorenal functions</measure>
    <time_frame>0~72 hours after the drug administration</time_frame>
    <description>ALT, AST, BUN, Cr, GFR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness for cranial nerve imaging</measure>
    <time_frame>Intraoperative period with cranial nerve exposure</time_frame>
    <description>Sensitivity, specificity, signal-to-background ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0~72 hours after the drug administration</time_frame>
    <description>Allergic reaction, changes in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functions of cranial nerves</measure>
    <time_frame>0~1 week after the drug administration</time_frame>
    <description>Physical examination of cranial nerves</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cranial Nerve Injuries</condition>
  <arm_group>
    <arm_group_label>FAM-NP41 Fluorescence Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be injected with FAM-NP41 preoperatively, and fluorescence imaging of cranial nerves will be evaluated after the craniotomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAM-NP41</intervention_name>
    <description>The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.</description>
    <arm_group_label>FAM-NP41 Fluorescence Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Enhanced brain MRI with or without cranial CT confirms a diagnosis of tumor in the&#xD;
             anterior skull base, the middle cranial fossa, or the posterior cranial fossa.&#xD;
             Structural images, DTI sequences and 3D-CISS sequences confirm that the tumor is&#xD;
             adjacent to the cranial nerve or the cranial nerve will be exposed during the&#xD;
             neurological surgery.&#xD;
&#xD;
          2. The body weight is within ±20% of standard body weight [0.7×(height cm-80)]kg;&#xD;
&#xD;
          3. The preoperative laboratory examination parameters of heart, lung, liver, kidney and&#xD;
             blood are all in the normal range;&#xD;
&#xD;
          4. Be able to understand the potential risks and benefits of the clinical trial, and sign&#xD;
             a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative hepatorenal insufficiency: ALT or AST increased ≥ 2 times than the upper&#xD;
             limit of normal range; serum creatinine &gt; 2.0 mg/ dL (177 μmol/L) or glomerular&#xD;
             filtration rate &gt; 30 ml/min×1.73 m2;&#xD;
&#xD;
          2. Positive reaction in the allergy test, or allergic constitution (such as allergic to&#xD;
             two or more foods/drugs, or known to be allergic to protein or to this polypeptide);&#xD;
&#xD;
          3. Preoperative imaging data (enhanced MRI) are incomplete;&#xD;
&#xD;
          4. Serious primary diseases involving important organs;&#xD;
&#xD;
          5. Mentally or physically disabled patients;&#xD;
&#xD;
          6. Alcohol abuse or long-term medication may affect the drug metabolism;&#xD;
&#xD;
          7. According to the judgment of the investigator, the potential intolerance to the drug&#xD;
             (such as weak or severe malnutrition);&#xD;
&#xD;
          8. Primary or secondary cranial nerve dysfunction, such as facial paralysis, hearing loss&#xD;
             caused by otitis media, etc.&#xD;
&#xD;
          9. Female patients undergoing neurosurgery during pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chenlong YANG, MD, PhD</last_name>
    <phone>+86-13511087060</phone>
    <email>vik.yang@pku.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun YANG, MD, PhD</last_name>
    <phone>+86-13901291211</phone>
    <email>yangjbysy@bjmu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cranial Nerve</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>Fluorescence Imaging</keyword>
  <keyword>Molecular Probe</keyword>
  <keyword>NP41</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cranial Nerve Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

